Machine Cognition

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina. The company's lead product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to penetrate the blood-brain barrier and selectively bind to the sigma-2 receptor complex. This mechanism is intended to displace toxic amyloid-beta oligomers from neuronal receptors, thereby restoring normal cellular housekeeping functions like protein trafficking and autophagy. Cognition is currently advancing zervimesine through multiple Phase 2 clinical trials for indications including Alzheimer's disease and dementia with Lewy bodies.